CAMP4 THERAPEUTICS CORPORATION (CAMP)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from CAMP's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from CAMP4 THERAPEUTICS CORPORATION's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $350,000 | $652,000 | $3M |
| Net income | -$49M | -$52M | -$80M |
| Free cash flow | -$45M | -$46M | -$30M |
| EPS (diluted) | -$124.80 | -$11.04 | -$2.65 |
| Operating margin | -14822.6% | -8142.3% | -1502.4% |
Superinvestors who own CAMP
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by CAMP4 THERAPEUTICS CORPORATION's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Kelly Gold Chief Financial Officer |
10,000 | $3.96 | $39,600 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when CAMP trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are CAMP4 THERAPEUTICS CORPORATION insiders buying the stock?
1 open-market insider purchase of CAMP in the last 12 months, from SEC Form 4 filings.
Companies like CAMP4 THERAPEUTICS CORPORATION
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.